Fig. 4From: Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registryAZL-M vs. ACE-inhibitors in patients with a 12 month follow-up–no treatment target adjustment. Legend: HT, hypertension; BMI, body mass indexBack to article page